相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
Mathew P. Martin et al.
ACS CHEMICAL BIOLOGY (2013)
2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors
Michael Siu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
Catherine C. Smith et al.
BLOOD (2013)
PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains
Sarah Picaud et al.
CANCER RESEARCH (2013)
PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
Britta Weigelt et al.
CLINICAL CANCER RESEARCH (2013)
Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Zhixiang Cheng et al.
CLINICAL CANCER RESEARCH (2013)
Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
Lewis R. Vidler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells
Ruwanthi N. Gunawardane et al.
MOLECULAR CANCER THERAPEUTICS (2013)
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Sarah Picaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Roles of p38 MAPKs in invasion and metastasis
Ivan del Barco Barrantes et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Christopher J. Ott et al.
BLOOD (2012)
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Panagis Filippakopoulos et al.
CELL (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation
Giovanna Bergamini et al.
NATURE CHEMICAL BIOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
William W. Lockwood et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of Separation
Livio Trusolino et al.
CANCER DISCOVERY (2012)
Kinase inhibitors: a new class of antirheumatic drugs
Vasileios C. Kyttaris
DRUG DESIGN DEVELOPMENT AND THERAPY (2012)
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents
Daigen Xu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
The Evolving War on Cancer
Daniel A. Haber et al.
CELL (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing
Oleg Fedorov et al.
CHEMISTRY & BIOLOGY (2011)
Bromodomains as therapeutic targets
Susanne Muller et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2011)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery
Martin Philpott et al.
MOLECULAR BIOSYSTEMS (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+myeloma cells
Vijay Ramakrishnan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex
Laura Hewitt et al.
JOURNAL OF CELL BIOLOGY (2010)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Chemical target and pathway toxicity mechanisms defined in primary human cell systems
Ellen L. Berg et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2010)
INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support
Jun Li et al.
NEOPLASIA (2010)
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
Dorothea Rudolph et al.
CLINICAL CANCER RESEARCH (2009)
Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design
Seungil Han et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Development of a Fluorescent-Tagged Kinase Assay System for the Detection and Characterization of Allosteric Kinase Inhibitors
Jeffrey R. Simard et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases:: Chemistry, biological activities, and molecular modeling
Yunsong Tong et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)
Zhen-Wei Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Selectivity-determining residues in Plk1
Michael Kothe et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo
Martin Steegmaier et al.
CURRENT BIOLOGY (2007)
BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo
Gopal P. Sapkota et al.
BIOCHEMICAL JOURNAL (2007)
Optimal description of a protein structure in terms of multiple groups undergoing TLS motion
J Painter et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2006)
Likelihood-enhanced fast translation functions
AJ McCoy et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2005)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
分享论文
